slides · global inventory
Image
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 119,566
Current window 90,301-90,330
Pages 3,986
Rows per page 30
Component
90,301-90,330 of 119,566
46
Includes a schematic diagram of the bispecific molecule on the left.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
47
The chart shows a clear performance advantage for the blue line (TCER®) over the grey lines.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
51
Includes ISH images, a prevalence table, and a dot plot comparing peptide density.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
57
The slide uses a log-linear plot to demonstrate drug clearance over time.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
60
The slide uses a visual metaphor of cell-to-cell interaction to illustrate the therapeutic mechanism.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
62
The chart is a dot plot showing quantitative target density (CpC) for two different peptide targets.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
66
The slide highlights the breadth of the company's intellectual property protection across major global regions.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
69
The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
01
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
07
Includes a cartoon illustration of a cell/virus character.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
13
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
16
Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
42
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
Includes survival curves (Kaplan-Meier style), median survival bar charts, and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
50
The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
Includes a comparative size diagram of the drug vs IgG antibody and a Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
56
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
62
The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient therapy thesis.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
63
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit